Thyrotropin
Also known as: recombinant human TSH, rhTSH, Thyrogen, Thyroid-stimulating hormone, Thyrotropin alfa, TSH
Source Thyrotropin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Thyrotropin, also known as recombinant human TSH (rhTSH, Thyrogen), is a prescription glycoprotein hormone approved for clinical use. It is administered by intramuscular or subcutaneous injection and is employed to raise circulating TSH levels for diagnostic purposes in thyroid evaluation.
Mechanism of Action
Recombinant TSH binds the thyrotropin receptor on thyroid follicular cells, activating the Gs‑protein‑cAMP signaling cascade. This stimulates thyroid hormone synthesis and release, and temporarily elevates serum TSH to enhance uptake of radioactive iodine or technetium during imaging studies.
What the Research Shows
The abstracts provided do not report direct clinical trials of recombinant TSH. Instead, they describe related investigations: an FcRn inhibitor that lowers pathogenic TSH‑receptor antibodies in thyroid eye disease, levothyroxine trials for subclinical hypothyroidism, and selenium supplementation in Hashimoto thyroiditis. These studies illuminate the role of TSH and its receptor in thyroid pathology but do not furnish efficacy or safety data for rhTSH itself.
Reported Benefits
Evidence in the cited literature does not assess therapeutic benefits of rhTSH. Its approved advantage is the ability to transiently increase TSH without withdrawing thyroid hormone therapy, facilitating diagnostic imaging of the thyroid gland.
Limitations of the Evidence
No randomized or observational studies of rhTSH are presented in the abstracts, leaving a gap in published efficacy and safety data beyond its approved diagnostic indication. The lack of direct evidence limits conclusions about broader clinical applications.
Safety Considerations
The provided abstracts do not describe adverse events related to recombinant TSH. Consequently, safety information specific to rhTSH cannot be derived from the cited sources; clinicians must rely on regulatory labeling and other literature for risk assessment.
How It Is Administered
Thyrotropin is supplied as a sterile protein solution for injection and is given either intramuscularly or subcutaneously. Dosing schedules are defined by the prescribing information and are not detailed in the cited abstracts.
Routes of Administration
Goals & Uses
- Thyroglobulin surveillance in thyroid cancerOncology / DiagnosticsHigh
- Stimulation of radioiodine uptake in metastatic thyroid cancerOncologyModerate
- Radioiodine remnant ablation in differentiated thyroid cancerOncologyHigh
- Stimulate thyroid hormone productionTherapeuticHigh
- Diagnostic radioiodine scintigraphyDiagnosticsHigh
- Diagnostic stimulation of thyroid tissueDiagnosticHigh
Contraindications
- Hypersensitivity to recombinant TSHAllergyHigh
- Large thyroid remnants with risk of swelling causing airway compromiseStructural / AnatomicalHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Pediatric use (children under 16)PopulationModerate
- Hypersensitivity to thyrotropin alfa or excipientsAllergy/ImmunologyHigh
Adverse Effects
- Injection site painLocalCommonPain at the injection site
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- Neurological deterioration / stroke-like symptomsNeurologicalRare
- FeverSystemicUncommonElevated body temperature
Drug Interactions
- LevothyroxineModerate
- Radioiodine (I-131)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Patients with known CNS metastasesOncologyRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Diagnostic stimulation of thyroid tissue in differentiated thyroid cancer
- United StatesApprovedApproved: Diagnostic stimulation of thyroid tissue in differentiated thyroid cancer, Preparation for radioiodine ablationMarketed as Thyrogen
- United KingdomApprovedApproved: Diagnostic stimulation of thyroid tissue in differentiated thyroid cancer
Approved as Thyrogen (rhTSH) for diagnostic use in the US, EU, and UK. Not indicated for routine thyroid hormone replacement.
Evidence & Sources
- Journal ArticleModerateKahaly GJ, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateStott DJ, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleHighSankoda A, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighHuwiler VV, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighConsortium on Thyroid and Pregnancy—Study Group on Preterm Birth, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleHighOsowiecka K, Myszkowska-Ryciak J2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What is recombinant human TSH?
Recombinant human TSH (rhTSH) is a laboratory‑produced version of the natural thyroid‑stimulating hormone, used to raise serum TSH levels for diagnostic imaging of the thyroid.
How is rhTSH administered?
It is given by injection, either into a muscle (intramuscular) or under the skin (subcutaneous), according to the dosing regimen approved by health authorities.
What is rhTSH approved for?
Regulatory approval is for diagnostic use—to stimulate thyroid uptake of radioactive tracers when patients are already on thyroid hormone therapy.
Can rhTSH treat thyroid disease?
The cited literature does not provide evidence that rhTSH treats hypothyroidism or other thyroid disorders; its role is limited to diagnostic stimulation.
Are there known side effects of rhTSH?
Adverse‑event data are not reported in the supplied abstracts, so safety must be inferred from other sources such as product labeling and post‑marketing surveillance.
What is Thyrotropin used for?
Thyrotropin is educationally associated with: Thyroglobulin surveillance in thyroid cancer, Stimulation of radioiodine uptake in metastatic thyroid cancer, Radioiodine remnant ablation in differentiated thyroid cancer, Stimulate thyroid hormone production, Diagnostic radioiodine scintigraphy, Diagnostic stimulation of thyroid tissue. Educational only — not medical advice.
How is Thyrotropin administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Thyrotropin?
Reported adverse effects include: Injection site pain, Hypersensitivity/anaphylaxis, Headache, Nausea, Fatigue, Vomiting, Neurological deterioration / stroke-like symptoms, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid Thyrotropin?
Recorded contraindications: Hypersensitivity to recombinant TSH, Large thyroid remnants with risk of swelling causing airway compromise, Pregnancy, Pediatric use (children under 16), Hypersensitivity to thyrotropin alfa or excipients. Consult a qualified clinician before use.